SGLT2 inhibitors ("-flozin" meds) improve all-cause and CV mortality in patients regardless of diabetes or HF status
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "SGLT2 Inhibitors ("-flozin" Meds) Improve All-cause and CV Mortality in Patients Regardless of Diabetes or HF Status." EE+ POEM Archive, John Wiley & Sons, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315226/all/SGLT2_inhibitors__"_flozin"_meds__improve_all_cause_and_CV_mortality_in_patients_regardless_of_diabetes_or_HF_status.
SGLT2 inhibitors ("-flozin" meds) improve all-cause and CV mortality in patients regardless of diabetes or HF status. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2024. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315226/all/SGLT2_inhibitors__"_flozin"_meds__improve_all_cause_and_CV_mortality_in_patients_regardless_of_diabetes_or_HF_status. Accessed November 10, 2024.
SGLT2 inhibitors ("-flozin" meds) improve all-cause and CV mortality in patients regardless of diabetes or HF status. (2024). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315226/all/SGLT2_inhibitors__"_flozin"_meds__improve_all_cause_and_CV_mortality_in_patients_regardless_of_diabetes_or_HF_status
SGLT2 Inhibitors ("-flozin" Meds) Improve All-cause and CV Mortality in Patients Regardless of Diabetes or HF Status [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2024. [cited 2024 November 10]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315226/all/SGLT2_inhibitors__"_flozin"_meds__improve_all_cause_and_CV_mortality_in_patients_regardless_of_diabetes_or_HF_status.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - SGLT2 inhibitors ("-flozin" meds) improve all-cause and CV mortality in patients regardless of diabetes or HF status
ID - 1315226
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315226/all/SGLT2_inhibitors__"_flozin"_meds__improve_all_cause_and_CV_mortality_in_patients_regardless_of_diabetes_or_HF_status
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -